TNNI3 and familial dilated cardiomyopathy: Blood-based biomarkers, including the N-terminal fragment of B-type natriuretic peptide (NT-proBNP), which predicts early cardiac enlargement, and cardiac troponin I (cTnI), a specific marker of myocardial injury, serve as useful screening tools for DCM.